Lipid Nanoparticle-mediated RNA Delivery for Immune Cell Modulation

Overview

Journal Eur J Immunol

Specialty Allergy & Immunology

Date 2024 Sep 16

PMID 39279550

Authors

Emily H Kim

Sridatta V Teerdhala

Marshall S Padilla

Ryann A Joseph

Jacqueline J Li

Rebecca M Haley

Michael J Mitchell

Affiliations

Soon will be listed here.

Abstract

Lipid nanoparticles (LNPs) have emerged as the preeminent nonviral drug delivery vehicles for nucleic acid therapeutics, as exemplified by their usage in the mRNA COVID-19 vaccines. As a safe and highly modular delivery platform, LNPs are attractive for a wide range of applications. In addition to vaccines, LNPs are being utilized as platforms for other immunoengineering efforts, especially as cancer immunotherapies by modulating immune cells and their functionality via nucleic acid delivery. In this review, we focus on the methods and applications of LNP-based immunotherapy in five cell types: T cells, NK cells, macrophages, stem cells, and dendritic cells. Each of these cell types has wide-reaching applications in immunotherapy but comes with unique challenges and delivery barriers. By combining knowledge of immunology and nanotechnology, LNPs can be developed for improved immune cell targeting and transfection, ultimately working toward novel clinical therapeutics.

References

Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M . Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020; 20(3):1578-1589. PMC: 7313236. DOI: 10.1021/acs.nanolett.9b04246. View

Labbe R, Vessillier S, Rafiq Q . Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses. 2021; 13(8). PMC: 8402758. DOI: 10.3390/v13081528. View

Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y . CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021; 139:111605. DOI: 10.1016/j.biopha.2021.111605. View

Kumar B, Connors T, Farber D . Human T Cell Development, Localization, and Function throughout Life. Immunity. 2018; 48(2):202-213. PMC: 5826622. DOI: 10.1016/j.immuni.2018.01.007. View

Francia V, Schiffelers R, Cullis P, Witzigmann D . The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy. Bioconjug Chem. 2020; 31(9):2046-2059. DOI: 10.1021/acs.bioconjchem.0c00366. View

Gao C, Cheng K, Li Y, Gong R, Zhao X, Nie G . Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy. Nano Lett. 2022; 22(22):8801-8809. DOI: 10.1021/acs.nanolett.2c01994. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

Nakamura T, Nakade T, Sato Y, Harashima H . Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles. Int J Pharm. 2023; 636:122810. DOI: 10.1016/j.ijpharm.2023.122810. View

Douka S, Brandenburg L, Casadidio C, Walther J, Garcia B, Spanholtz J . Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells. J Control Release. 2023; 361:455-469. DOI: 10.1016/j.jconrel.2023.08.014. View

10.

Zhou X, Liu Y, Hu M, Wang M, Liu X, Huang L . Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy. Sci Adv. 2021; 7(8). PMC: 7888957. DOI: 10.1126/sciadv.abb6596. View

11.

Nguyen L, Lucke-Wold B, Mookerjee S, Cavendish J, Robson M, Scandinaro A . Role of sigma-1 receptors in neurodegenerative diseases. J Pharmacol Sci. 2015; 127(1):17-29. DOI: 10.1016/j.jphs.2014.12.005. View

12.

Goldberg M . Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019; 19(10):587-602. DOI: 10.1038/s41568-019-0186-9. View

13.

Yang C, Siebert J, Burns R, Gerbec Z, Bonacci B, Rymaszewski A . Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat Commun. 2019; 10(1):3931. PMC: 6718415. DOI: 10.1038/s41467-019-11947-7. View

14.

Billingsley M, Hamilton A, Mai D, Patel S, Swingle K, Sheppard N . Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. Nano Lett. 2021; 22(1):533-542. PMC: 9335860. DOI: 10.1021/acs.nanolett.1c02503. View

15.

Yunna C, Mengru H, Lei W, Weidong C . Macrophage M1/M2 polarization. Eur J Pharmacol. 2020; 877:173090. DOI: 10.1016/j.ejphar.2020.173090. View

16.

Naik S, Larsen S, Cowley C, Fuchs E . Two to Tango: Dialog between Immunity and Stem Cells in Health and Disease. Cell. 2018; 175(4):908-920. PMC: 6294328. DOI: 10.1016/j.cell.2018.08.071. View

17.

Tonn T, Schwabe D, Klingemann H, Becker S, Esser R, Koehl U . Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013; 15(12):1563-70. DOI: 10.1016/j.jcyt.2013.06.017. View

18.

Li L, Liu L, Feller S, Allen C, Shivakumar R, Fratantoni J . Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 2009; 17(3):147-54. PMC: 2821468. DOI: 10.1038/cgt.2009.61. View

19.

Wang T, Larcher L, Ma L, Veedu R . Systematic Screening of Commonly Used Commercial Transfection Reagents towards Efficient Transfection of Single-Stranded Oligonucleotides. Molecules. 2018; 23(10). PMC: 6222501. DOI: 10.3390/molecules23102564. View

20.

Kim D, Wu Y, Shim G, Oh Y . Lipid Nanoparticle-Mediated Lymphatic Delivery of Immunostimulatory Nucleic Acids. Pharmaceutics. 2021; 13(4). PMC: 8103501. DOI: 10.3390/pharmaceutics13040490. View